NasdaqGS - Delayed Quote USD

Bolt Biotherapeutics, Inc. (BOLT)

1.1100 -0.0300 (-2.63%)
At close: April 19 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Randall C. Schatzman Ph.D. CEO & Director 829.32k -- 1955
Dr. Edgar George Engleman M.D. Founder & Independent Director 38.75k -- 1946
Mr. William P. Quinn CFO & Secretary 594.56k -- 1971
Mr. Grant Yonehiro C.F.A., M.B.A. Chief Business Officer 544.71k -- 1964
Dr. Edith A. Perez M.D. Chief Medical Officer 668.32k -- 1957
Mr. Wesley Burwell VP & Head of Human Resources -- -- --
Dr. Nathan Ihle Ph.D. Senior Vice President of Pharmaceutical Operations -- -- --

Bolt Biotherapeutics, Inc.

900 Chesapeake Drive
Redwood City, CA 94063
United States
650 665 9295 https://www.boltbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
100

Description

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Corporate Governance

Bolt Biotherapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Bolt Biotherapeutics, Inc. Earnings Call

Related Tickers

ACHL Achilles Therapeutics plc
0.7829
-2.14%
 
NXTC NextCure, Inc.
1.6000
+1.91%
 
BCAB BioAtla, Inc.
2.1050
-13.37%
 
SNSE Sensei Biotherapeutics, Inc.
0.9700
+1.04%
 
CTMX CytomX Therapeutics, Inc.
1.6700
-3.47%
 
CMPX Compass Therapeutics, Inc.
1.4700
-1.34%
 
ALGS Aligos Therapeutics, Inc.
0.7500
-5.43%
 
LVTX LAVA Therapeutics N.V.
2.7100
-4.24%
 
DSGN Design Therapeutics, Inc.
3.7000
-1.07%
 
GBIO Generation Bio Co.
2.8000
+0.72%